100935-99-7|ent Naxagolide HCl|(4aS-trans)-3,4,4a,5,6,10b-Hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol Hydrochloride|-范德生物科技公司

ent Naxagolide HCl

NMR下载 COA and HPLC MSDS下载
names：
(4aS-trans)-3,4,4a,5,6,10b-Hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol Hydrochloride
CAS号：
100935-99-7
MDL Number：
MF(分子式)： C15H22ClNO2 MW(分子量)： 283.79
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	ent Naxagolide HCl
英文别名	ent Naxagolide Hydrochloride; ent Naxagolide HCl; MK-458; MK 458; MK458; Naxagolide HCl; Naxagolide Hydrochloride;
CAS号	100935-99-7
Inchi	InChI=1S/C15H21NO2.ClH/c1-2-7-16-8-9-18-15-13-10-12(17)5-3-11(13)4-6-14(15)16;/h3,5,10,14-15,17H,2,4,6-9H2,1H3;1H/t14-,15-;/m0./s1
InchiKey	NNEACMQMRLNNIL-YYLIZZNMSA-N
分子式 Formula	C15H22ClNO2
分子量 Molecular Weight	283.79
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	ent Naxagolide HCl(CAS:100935-99-7 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	ent Naxagolide is a S-isomer of Naxagolide. ent Naxagolide is a dopamine D2-receptor agonist for the treatment of extrapyramidal disorders, also being an antiparkinson agent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Moribe K, Pongpeerapat A, Tozuka Y, Yamamoto K. Drug nanoparticle formation from drug/HPMC/SDS ternary ground mixtures. Pharmazie. 2006 Feb;61(2):97-10[1]PubMed PMID: 16526554.

[2]Varshosaz J, Tavakoli N, Eram SA. Use of natural gums and cellulose derivatives in production of sustained release metoprolol tablets. Drug Deliv. 2006 Mar-Apr;13(2):113-9. PubMed PMID: 16423799.

[3] Krishnaiah YS, Al-Saidan SM, Chandrasekhar DV, Satyanarayana V. Controlled in vivo release of nicorandil from a carvone-based transdermal therapeutic system in human volunteers. Drug Deliv. 2006 Jan-Feb;13(1):69-77. PubMed PMID: 16401596.

[4] Rodriguez-Tenreiro C, Alvarez-Lorenzo C, Rodriguez-Perez A, Concheiro A, Torres-Labandeira JJ. New cyclodextrin hydrogels cross-linked with diglycidylethers with a high drug loading and controlled release ability. Pharm Res. 2006 Jan;23(1):121-30. Epub 2006 Dec 7. PubMed PMID: 16320002.

[5] McInnes FJ, Thapa P, Baillie AJ, Welling PG, Watson DG, Gibson I, Nolan A, Stevens HN. In vivo evaluation of nicotine lyophilised nasal insert in sheep. Int J Pharm. 2005 Nov 4;304(1-2):72-82. Epub 2005 Sep 23. PubMed PMID: 16183221.

6: Cao QR, Choi YW, Cui JH, Lee BJ. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen. J Control Release. 2005 Nov 28;108(2-3):351-61. Epub 2005 Sep 12. PubMed PMID: 16154656.7: El-Nabarawi MA. Modulation of Tenoxicam release from hydrophilic matrix: modulator membrane versus rate-controlling membrane. Chem Pharm Bull (Tokyo). 2005 Sep;53(9):1083-7. PubMed PMID: 16141572.8: Mehuys E, Remon JP, Korst A, Van Bortel L, Mols R, Augustijns P, Porter C, Vervaet C. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core. J Control Release. 2005 Oct 20;107(3):523-36. PubMed PMID: 16055224.9: Ruenraroengsak P, Florence AT. The diffusion of latex nanospheres and the effective (microscopic) viscosity of HPMC gels. Int J Pharm. 2005 Jul 25;298(2):361-6. PubMed PMID: 15939561.10: Wang CY, Ho HO, Lin LH, Lin YK, Sheu MT. Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects. Int J Pharm. 2005 Jun 13;297(1-2):89-97. PubMed PMID: 15885936.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开